References
- Ancoli-Israel S, Roth T. Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. Sleep22, 347–353 (1999).
- Silber MH. Clinical practice: chronic insomnia. N. Engl. J. Med.353, 803–810 (2005).
- Roth T. Insomnia: definition, prevalence, etiology and consequences. J. Clin. Sleep Med.3, 7–10 (2007).
- Budur K, Rodriguez C, Foldvary-Schaefer N. Advances in treating insomnia. Cleve. Clin. J. Med.74(4), 251–252, 255–258, 261–262 (2007).
- Kim K, Uchiyama M, Okawa M et al. An epidemiological study of insomnia among the Japanese general population. Sleep23, 41–47 (2000).
- Liu X, Uchiyama M, Kim K et al. Sleep loss and daytime sleepiness in the general adult population of Japan. Psychiatry Res.93, 1–11 (2000).
- Uchiyama M, Kim K. Classification epidemiology and impact of sleep disorders. Pharma. Medica.18, 13–18 (2000).
- Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am. Fam. Physician76, 517–526 (2007).
- Mann K, Bauer H, Hiemke C et al. Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretion. Eur. Neuropsychopharmacol.6, 163–168 (1996).
- Hedner J, Yaeche R, Emilien G, Farr I, Salinas E. Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zalepoln Clinical Investigator Study group. Int. J. Geriatr. Psychiatry15, 704–712 (2000).
- Doghramji K. Melatonin and its receptors: a new class of sleep-promoting agents. J. Clin. Sleep Med.3, 17–23 (2007).
- Kato K, Hirai K, Nishiyama K et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology48, 301–310 (2005).
- Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr. Med. Res. Opin.23, 1005–1014 (2007).
- Erman M, Seiden D, Zammit G et al. An efficacy, safety, and dose–response study of ramelteon in patients with chronic primary insomnia. Sleep Med.7, 17–24 (2006).
- Zammit G, Erman M, Wang-Weigand S et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J. Clin. Sleep Med.3, 495–504 (2007).
- Johnson MW, Suess PE, Griffiths RR. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch. Gen. Psychiatry63, 1149–1157 (2006).
- Mayer G, Wang-Weigand S, Roth-Schechter B, Lehmann R, Staner C, Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep32, 351–360 (2009).
- Richardson GS, Zammit G, Wang-Weigand S, Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study. J. Clin. Psychiatry70, 467–476 (2009).
- Roth T, Seiden D, Sainati S Wang-Weigand S, Zhang J, Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med.7, 312–318 (2006).
- Roth T, Roehrs TA, Vogel GW, Dement WC. Evaluation of hypnotic medications. In: Clinical Evaluation of Psychotropic Drugs Principles and Guidelines (Volume 22). Prien RF, Robinson DS (Eds). Raven Press, NY, USA, 579–592 (1994).
- Uchiyama M, Hamamura M, Kuwano T, Nishiyama H, Nagata H, Uchimura N. Evaluation of subjective efficacy and safety of ramelteon in Japanese subjects with chronic insomnia. Sleep Med. DOI: 10.1016/j.sleep.2010.08.010 (2010) (Epub ahead of print).
- Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr. Serv.56, 332–343 (2005).
- Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J. Clin. Psychiatry66, 31–41 (2005).
- Estivill E, Bov A, Garca-Borreguero D et al. Drug treatment, definition and diagnosis for insomnia: methods. Clin. Drug Investig.23, 6 (2003).